

Translational Epigenetics

# PHARMACOEPIGENETICS

---

Volume 10

*Edited by*

RAMÓN CACABELOS

*EuroEspes Biomedical Research Center, Institute of Medical Science and Genomic Medicine,  
Corunna, Spain; Chair of Genomic Medicine, Continental University Medical School, Huancayo, Peru*



**ACADEMIC PRESS**

An imprint of Elsevier

# Contents

---

<b>Contributors</b>	<b>xi</b>		
<b>Pharmacoepigenetics: A Long Way Ahead</b>	<b>xv</b>		
<b>1. The Epigenetic Machinery in the Life Cycle and Pharmacoepigenetics</b>			
RAMÓN CACABELOS, IVÁN TELLADO, AND PABLO CACABELOS			
1.1 Introduction	1		
1.2 The Epigenetic Machinery	2		
1.3 Singular Epigenetic Phenomena	53		
1.4 Evolution	62		
1.5 Population Epigenetics	63		
1.6 Fertility and Gestation	63		
1.7 Placenta	70		
1.8 Lactation	71		
1.9 Development	72		
1.10 Maturation, Aging, and Longevity	74		
1.11 Epigenetic Mendelian Disorders	76		
1.12 Pharmacoepigenetics Network	76		
1.13 Conclusions	82		
References	83		
<b>2. Pharmacoepigenetics: Basic Principles for Personalized Medicine</b>			
ALEKSANDRA MAJCHRZAK-CELIŃSKA, AND WANDA BAER-DUBOWSKA			
2.1 Introduction: Personalized or Precision Medicine?	101		
2.2 Pharmacogenomics: The Core Discipline of Personalized Medicine	102		
2.3 Pharmacoepigenetics: An Additional Layer of Regulatory and Environmental Exposure Information Affecting Individual Drug Response	103		
2.4 Pharmacoepigenetics in Personalized/Precision Medicine	105		
2.5 Epigenetic Tools in Personalized Cell Therapy	108		
2.6 Conclusions and Perspectives	109		
References	109		
<b>3. Epigenetic Mechanisms in the Regulation of Drug Metabolism and Transport</b>			
OSCAR TEJIDO			
3.1 Introduction	113		
3.2 Epigenetic Mechanisms	114		
3.3 Epigenetic Regulation of Genes Associated With Drug Metabolism and Transport (Pharmacoepigenetics)	116		
3.4 Epigenetics of Drug Resistance	121		
3.5 Conclusions and Future Directions	124		
References	124		
<b>4. MicroRNA-Dependent Gene Regulation of the Human Cytochrome P450</b>			
DONGYING LI, WILLIAM H. TOLLESON, DIANKE YU, SI CHEN, LEI GUO, WENMING XIAO, WEIDA TONG, AND BAITANG NING			
4.1 Introduction		129	
4.2 Molecular Mechanisms for the Regulation of CYP Expression by miRNAs		129	
4.3 Methods for Investigating the Regulation of CYP Expression by miRNAs		130	
4.4 Clinical Implications		134	
4.5 Conclusions		136	
References		136	
<b>5. Pathoepigenetics: The Role of Epigenetic Biomarkers in Disease Pathogenesis</b>			
RAMÓN CACABELOS			
5.1 Introduction		139	
5.2 Cardiovascular Disorders		140	
5.3 Atherosclerosis		142	
5.4 Hypertension		143	
5.5 Venous Thromboembolism		143	
5.6 Cancer		143	
5.7 Metabolic Disorders		159	
5.8 Immunological and Inflammatory Disorders		163	
5.9 Other Pathoepigenetic Disorders		166	
5.10 Gut Microbiome		173	
5.11 Pluripotent Stem Cells		173	
5.12 Epigenetic Biomarkers		176	
5.13 Conclusions		177	
References		177	
<b>6. Pharmacoepigenetic Processors: Epigenetic Drugs, Drug Resistance, Toxicopigenetics, and Nutriepigenetics</b>			
RAMÓN CACABELOS, JUAN C. CARRIL, ANA SANMARTÍN, AND PABLO CACABELOS			
6.1 Introduction		191	
6.2 Pharmacoepigenetics Apparatus		192	
6.3 Epigenetic Drugs		256	
6.4 Other Pharmacoepigenetics-Related Products		331	
6.5 lncRNAs, miRNAs, and Derived Technologies		338	
6.6 Pharmacogenetics of Epigenetic Drugs		347	
6.7 Pharmacoepigenetic Effects of Selected Therapeutic Interventions		347	
6.8 Drug Resistance		364	

6.9 Pharmacoeigenetic Predictors of Drug Efficacy and Safety	373	11. Bromodomain Inhibition and Its Application to Human Disease	475
6.10 Toxicoeigenetics	374	NATHAN J. DUPPER, YINGSHENG ZHOU, JÉRÔME GOVIN, AND CHARLES E. MCKENNA	
6.11 Nutriepigenetics	391	11.1 The Role of Histones in Chromatin-Signaling Pathways	475
6.12 Conclusions	401	11.2 Bromodomains and Their Inhibitors	476
References	402	11.3 BET Bromodomain Inhibition in Pathological Contexts	483
7. Pharmacoeigenetics of Novel Nucleoside DNA Methyltransferase Inhibitors		11.4 Bromodomain Inhibition and Protozoal Infections	485
RICHARD DAIFUKU		11.5 Bromodomain Inhibition and Fungal Infections	487
7.1 Introduction	425	11.6 Bromodomain Inhibition and Viral Infections	488
7.2 Approved DNMT Inhibitors	428	11.7 Future Directions	489
7.3 DNMT Inhibitors in Clinical Development	429	Acknowledgments	489
7.4 DNMT Inhibitors in Preclinical Development	430	References	489
7.5 Conclusion	432	12. Epigenetic Drug Discovery for Cancer	
Acknowledgments	432	BO LIU, AND RONG-RONG HE	
References	432	12.1 Introduction	493
8. Pharmacoeigenetics: Novel Mechanistic Insights in Drug Discovery and Development Targeting Chromatin-Modifying Enzymes		12.2 Bromodomain (BRD) Proteins and Their Interaction With Small-Molecule Inhibitors in Cancer	493
RAVIKUMAR VILWANATHAN, ANUSHA CHIDAMBARAM, AND RAMESH KUMAR CHIDAMBARAM		12.3 Histone Acetyltransferases and Their Interaction With Small-Molecule Inhibitors in Cancer	494
8.1 Introduction	437	12.4 Histone Deacetylases and Their Interaction With Small-Molecule Inhibitors in Cancer	496
8.2 Epigenetic Mechanisms	437	12.5 Sirtuins and Their Interaction With Small-Molecule Activators/Inhibitors in Cancer	497
8.3 Histone Deacetylase Inhibitors	439	References	499
8.4 Designing Pharmacophore-Based HDAC Inhibitors	441	13. Pharmacoeigenetics of Histone Deacetylase Inhibitors in Cancer	
8.5 Peptide-Based Macrocyclic Histone Deacetylase Inhibitors	441	NIKOLAOS GARMPI, CHRISTOS DAMASKOS, ANNA GARMPI, SERENA VALSAMI, AND DIMITRIOS DIMITROULIS	
8.6 Pharmacophore-Based Design and Development of Inhibitors Targeting Chromatin-Modifying Enzymes	442	13.1 Introduction	501
8.7 Conclusion	443	13.2 Histone Acetylation and Deacetylation	501
References	444	13.3 Histone Deacetylases	502
9. Pharmacoeigenetics of EZH2 Inhibitors		13.4 Histone Deacetylase Inhibitors	505
CAMERON LINDSAY, MORRIS KOSTIUK, AND VINCENT L. BIRON		13.5 Histone Deacetylase Inhibitors: Mechanism of Action	509
9.1 Polycomb Group Proteins	447	13.6 Conclusion	513
9.2 EZH2	447	References	514
9.3 Categories of EZH2 Inhibitors	454	14. Pharmacoeigenetics of LSD1 Inhibitors in Cancer	
References	458	BIN YU, AND HONG-MIN LIU	
10. Regulators of Histone Acetylation: Bromodomain Inhibitors		14.1 Introduction	523
TOMOMI NOGUCHI-YACHIDE		14.2 LSD1-Mediated Demethylation of Histone Lysines	523
10.1 Introduction	463	14.3 The Development of LSD1 Inhibitors for Cancer Therapy	524
10.2 BET Family Proteins	465	14.4 Conclusions	528
10.3 Polypharmacology	468	References	528
10.4 Non-BET Bromodomain Inhibitors	470	15. Pharmacoeigenetic Considerations for the Treatment of Breast Cancer	
10.5 Conclusions and Prospects	470	R. ZEITOUN, E. ABOU DIWAN, R. NASR, AND N.K. ZGHEIB	
References	471	15.1 Breast Cancer	531
		15.2 Pharmacoeigenetics of Breast Cancer	532

15.3 Role of Circulating Pharmacoepigenetic Biomarkers	535	20.2 Epigenomics in Rheumatic Diseases	587
15.4 Epidrugs in Breast Cancer	536	20.3 Epigenetics and Response to Therapy	590
15.5 Conclusion	536	20.4 Conclusions	593
References	537	References	594
<b>16. Pharmacoepigenetics of Acute Myeloid Leukemia</b>		<b>21. Pharmacoepigenetics of Systemic Lupus Erythematosus</b>	
DIBYENDU DUTTA, AND SEAH H. LIM		CHRISTIAN MICHAEL HEDRICH	
16.1 Introduction	541	21.1 Introduction	597
16.2 Epigenetic Mechanisms in AML	542	21.2 DNA Methylation and DNA Hydroxymethylation	598
16.3 Epigenetic Modifiers in AML Therapy	543	21.3 Histone Modifications	601
16.4 Epigenetic Modifiers as Primers of Induction Therapy of AML	546	21.4 Noncoding RNAs Shape the Epigenome	602
16.5 Epigenetic Modifiers as Primers of AML Immunotherapy	546	21.5 Environmental Factors and Behavior	603
16.6 Concluding Remarks	547	21.6 Future Directions	604
References	547	21.7 Conclusions	605
		References	605
<b>17. Therapeutic Potential of Pharmacoepigenetics in Cholangiocarcinoma</b>		<b>22. Epigenetics and Pharmacoepigenetics of Neurodevelopmental and Neuropsychiatric Disorders</b>	
COLM J. O'ROURKE, LETIZIA SATRIANO, DOUGLAS V.N.P. OLIVEIRA, PATRICIA MUNOZ-GARRIDO, AND JESPER B. ANDERSEN		RAMÓN CACABELOS	
17.1 Introduction	551	22.1 Introduction	609
17.2 Personalizing Epigenetic Therapy in Cholangiocarcinoma	552	22.2 Neuropsychopharmacology and the Epigenetic Conundrum in CNS Disorders	610
17.3 Contextualizing Epigenetic Therapy in Cholangiocarcinoma	553	22.3 Brain Development	612
17.4 Conclusions and Future Directions	558	22.4 Memory and Learning	619
References	560	22.5 Stressful Events	621
		22.6 Behavior	623
 		22.7 Neurodevelopmental Disorders	625
<b>18. Pharmacoepigenetics in Type 2 Diabetes Mellitus</b>		22.8 Mood Disorders	643
JOHANNA K. DISTEFANO, AND RICHARD M. WATANABE		22.9 Anxiety Disorders	656
18.1 Overview of Type 2 Diabetes (T2D): Prevalence, Diagnosis, and Clinical Management	563	22.10 Psychosis and Schizophrenia	658
18.2 Pharmacogenomics of T2D	565	22.11 Personality Disorders	670
18.3 Common Epigenetic Modifications in T2D	565	22.12 Substance Use Disorders	679
18.4 Epigenetic Modifications and Interindividual Variation in Response to Antidiabetic Drugs	568	22.13 Eating Disorders	681
18.5 Conclusions: Implications for Treatment Strategies and Precision Medicine	569	22.14 Sleep Disorders	682
References	570	22.15 Epilepsy	682
		22.16 Brain Cancer	683
 		22.17 Cerebrovascular Disorders	691
<b>19. Pharmacoepigenetics of Immunological Disorders</b>		22.18 Conclusions	693
RAMAZAN REZAEI, SAEED ASLANI, AND MAHDI MAHMOUDI		References	694
19.1 Pharmacoepigenetics and Autoimmune Diseases	573		
19.2 Pharmacoepigenetics and Immunodeficiency	577	<b>23. Pharmacoepigenetics and Toxicopigenetics in Neurodevelopmental Disorders</b>	
19.3 Pharmacoepigenetics and Hypersensitivity	580	NGUYEN QUOC VUONG TRAN, AND KUNIO MIYAKE	
19.4 Conclusion and Prospectus	582	23.1 Introduction	711
Acknowledgments	582	23.2 Sensitive Periods for Environmental Toxicant Exposure and NDDs	711
References	582	23.3 Epigenetics and Drug Exposure in Neurodevelopmental Disorders	713
		23.4 Epigenetics and Environmental Toxicants in Neurodevelopmental Disorders	714
 		23.5 Conclusion and Perspectives	716
<b>20. Pharmacoepigenetics of Rheumatic Disorders</b>		References	716
P. CASTRO-SANTOS, AND R. DÍAZ-PEÑA			
20.1 Introduction	587		

<b>24. Pharmacoeugenetics of Autism Spectrum Disorder</b>		<b>29. Pharmacological Nicotinamide: Mechanisms Centered Around SIRT1 Activity</b>	
MERIEM HAMZA, SOUMEYYA HALAYEM, RIDHA MRAD, AND AHLEM BELHADJ		EUN SEONG HWANG	
24.1 Introduction	721	29.1 Biochemistry and Functions of NAD <sup>+</sup> and NAM	781
24.2 Pharmacotherapy of Autism Spectrum Disorder in the Light of Epigenetics	721	29.2 Regulation of SIRT1 by NAM	785
24.3 Epidrugs	725	29.3 Therapeutic Effects of NAM and Underlying Mechanisms	789
24.4 RNA-Based Therapies	727	Acknowledgments	793
24.5 Dietary Epigenetic Therapeutics	727	References	793
24.6 Conclusion and Perspectives	729	<b>30. Pharmacoeugenetics and Pharmacoeugenomics of Valproate in Neurodegenerative Disease</b>	
References	729	ASEEL EID, AND JASON R. RICHARDSON	
<b>25. Pharmacoeugenetics of Antipsychotic Drugs</b>		30.1 Introduction	801
BABU SWATHY, BINITHAMOL K. POLAKKATTIL, AND MOINAK BANERJEE		30.2 History of Valproate	802
25.1 Introduction	733	30.3 Neuroprotective Properties of Valproate in Neurodegenerative Disease	802
25.2 Mechanisms of Epigenomic Regulation by Drugs	733	30.4 Conclusion	807
25.3 Epigenetic Effects of Antipsychotic Drugs	733	References	813
25.4 Regulation of Immune Response by Antipsychotic Drugs	736	<b>31. Pharmacoeugenetics of Statins</b>	
25.5 Conclusion	736	TOMÁS ZAMBRANO, KATHLEEN SAAVEDRA, AND LUIS A. SALAZAR	
References	737	31.1 Statins: An Overview	817
<b>26. Pharmacoeugenetics of Bipolar Disorder</b>		31.2 Genetics and Statin Response	818
GABRIEL R. FRIES		31.3 Epigenetics and Therapeutic Variability of Statin Treatment	819
26.1 Introduction	741	31.4 Pleiotropic and Adverse Effects of Statins Mediated by Epigenetic Mechanisms	822
26.2 Pharmacotherapy of Bipolar Disorder	741	Acknowledgments	823
26.3 Genetic Biomarkers of Treatment Response in Bipolar Disorder	742	References	823
26.4 Pharmacoeugenetics of Bipolar Disorder	742	<b>32. Pharmacoeugenetics of Memantine in Dementia</b>	
26.5 Clinical Implications and Future Directions	744	YILDIZ DINCER	
References	744	32.1 Overview of Epigenetic Modifications	828
<b>27. Pharmacoeugenetics of Major Depression</b>		32.2 Pharmacoeugenetics	829
GABRIEL R. FRIES, HARRIS A. EYRE, CHAD BOUSMAN, JOAO QUEVEDO, AND BERNHARD T. BAUNE		32.3 Epigenetically Mediated Effects on Memantine Response	830
27.1 Introduction	747	32.4 The Intersection of Epigenetics and Memantine	830
27.2 Clinical Pharmacogenetic Studies in Major Depression	747	32.5 Conclusions and Future Perspective	833
27.3 Guidelines and Commercial Tools in Major Depression	751	References	833
27.4 Discussion	752	<b>33. Epigenetics in Doxorubicin Cardiotoxicity</b>	
References	752	LUCIANA L. FERREIRA, PAULO J. OLIVEIRA, AND TERESA CUNHA-OLIVEIRA	
<b>28. Pharmacoeugenetics of Vertigo and Related Vestibular Syndromes</b>		33.1 Introduction	837
JOAQUÍN GUERRA, AND RAMÓN CACABELOS		33.2 Doxorubicin: From Chemotherapeutic to Cardiotoxic	837
28.1 Introduction	755	33.3 Doxorubicin Risk: Genetic and Epigenetic Profiling	838
28.2 Pathogenic Mechanisms of Vertigo and Vestibular Syndromes	755	33.4 Interplay Between DOX, Energy Metabolism, and Epigenetics in DOX Cardiotoxicity	839
28.3 Genetics of Vertigo and Related Syndromes	757	33.5 Conclusions	842
28.4 Pharmacology of Vertigo	759	Acknowledgments	843
28.5 Pharmacogenetics of Vertigo	761	References	843
28.6 Epigenetics of Vertigo	763		
28.7 Pharmacoeugenetics of Vertigo	765		
28.8 Conclusion	776		
References	776		

### 34. Pharmacoepigenerics of *Brassica*-Derived Compounds

NIEVES BAENAS, AND ANIKA E. WAGNER

34.1 General Health-Promoting Effects of Compounds Derived From <i>Brassicaceae</i>	847
34.2 Epigenetic Modulation by <i>Brassicaceae</i>	849
34.3 Pharmacoepigenerics of <i>Brassica</i> -Derived Compounds in the Context of Chronic Diseases	851
34.4 Pharmacoepigenerics of <i>Brassicaceae</i> : a Potential Element in Disease Prevention	854
Acknowledgments	855
References	855

### 35. Pharmacoepigenerics of Chinese Herbal Components in Cancer

LINLIN LU, QIAN FENG, TAO SU, YUANYUAN CHENG, ZHIYING HUANG, QIUJU HUANG, AND ZHONGQIU LIU

35.1 Introduction	859
35.2 Epigenetic Modification Types	859
35.3 Epigenetic Biomarkers in Various Cancers	863
35.4 Chinese Herbal Medicines Used as Epigenetic Modulators	863
35.5 Conclusion and Perspectives	868
References	868

### 36. Epigenetics of Aging and Age-Related Disorders

CORINNE SIDLER, OLGA KOVALCHUK, AND IGOR KOVALCHUK

36.1 Introduction	871
36.2 Epigenetics of Aging	872
36.3 Epigenetics of Age-Related Disorders	877
36.4 Conclusions	879
Conflict of Interest Statement	879
Acknowledgments	879
References	879

### 37. Epigenetics of Aging and Cancer: A Comprehensive Look

ANTJA-VOY HARTLEY, MATTHEW MARTIN, JIAMIN JIN, AND TAO LU

37.1 Introduction	885
37.2 Epigenetic Signatures in Aging	885
37.3 Epigenetic Signatures in Cancer	888
37.4 Epigenetic Changes Linking Aging and Cancer	890
37.5 Therapeutic Targets and Current Pharmacoepigenerics-Based Strategies for Aging and Cancer	894
37.6 Perspectives	895
Acknowledgments	895
References	896

### 38. Epigenetics and Pharmacoepigenerics of Age-Related Neurodegenerative Disorders

RAMÓN CACABELOS, PABLO CACABELOS, AND JUAN C. CARRIL

38.1 Introduction	903
38.2 Epigenetic Mechanisms of Aging	904
38.3 Brain Aging	908
38.4 Progeroid Syndromes	909
38.5 Alzheimer's Disease	910
38.6 Other Forms of Dementia	925
38.7 Parkinson's Disease	926
38.8 Multiple Sclerosis	935
38.9 Amyotrophic Lateral Sclerosis	936
38.10 Polyglutamine Disorders	937
38.11 Other Age-Related Degenerative Disorders	938
38.12 Conclusions	939
References	939

### Index 951